---
title: Ascendia Announces A New Patent On Its ASD-002 Program
description: Read here as Ascendia Pharmaceuticals announce a new patent on its ASD-002 program - Clopidogrel, top-selling blood thinner medicine. Learn more.
---

[Pharmaceutical Industry Blog - Ascendia Pharmaceutical Solutions Blog ](https://ascendiacdmo.com/newsroom)

# [Ascendia Announces A New Patent On Its ASD-002 Program](https://ascendiacdmo.com/newsroom/2017/01/06/ascendia-pharmaceuticals-announces-issuance-of-a-new-patent-on-its-asd-002-program-for-acute-coronary-syndrome)

 Written by [ascendia](https://ascendiacdmo.com/newsroom/author/ascendia) | Jan 6, 2017 5:00:00 AM

## An injectable formulation of the platelet aggregation inhibitor drug clopidogrel

NORTH BRUNSWICK, NJ — (BUSINESS WIRE) — January 06, 2017 — Ascendia Pharmaceuticals, a specialty pharmaceutical company engaged in nano-formulation design, development, and manufacture for poorly soluble molecules, today announced that it has been awarded a new patent. U.S. Patent No. 9,480,680, entitled “Stable Pharmaceutical Composition of Clopidogrel Free Base for Oral and Parenteral Delivery”, describes the application of Ascendia’s EmulSol nanotechnology to formulate a stable, ready-to-use, rapid-onset, injectable form of clopidogrel.

### About ASD-002

Clopidogrel, a top-selling blood thinner medicine, has never been successfully developed in an injectable dosage form due to its inherent chemical instability and poor solubility.

“There is a significant unmet medical need for a parenteral clopidogrel dosage form for the treatment of Acute Coronary Syndrome under life-threatening situations,” said Jingjun “Jim” Huang, Ph.D., CEO of Ascendia. “With our nanoemulsion platform technology, Ascendia has demonstrated that a ready-to-use, stable and soluble, parenteral form of clopidogrel is both technically and commercially feasible.” When a patient presents with a suspected coronary event, a high oral dose of clopidogrel is frequently administered as the only available forms of clopidogrel are tablets – not ideal in an emergency setting. Also, when delivered orally, there is a significant delay in the time required for the medicine to become fully absorbed and effective.

ASD-002 can be administered as a single high-dose injection of clopidogrel, capable of overcoming CYP2C19 resistance in a percutaneous coronary intervention (PCI) setting (which 30% of patients experience). Thus ASD-002 will address the unmet need for rapid platelet inhibition, while reducing bleeding risk, associated with newer P2Y12 agents, and has the potential to expand the $2 billion PCI market in peripheral artery disease. ASD-002 for injection also has the potential to provide an advantage compared to the recently approved IV anti-thrombotic drug cangrelor, as ASD-002 should not have an indication exclusion for patients currently on a P2Y12 inhibitor.

### About Ascendia Pharmaceuticals LLC

Ascendia is a specialty pharmaceutical company dedicated to developing enhanced formulations of existing drug products, and enabling formulations for pre-clinical and clinical stage drug candidates. We specialize in creating formulation solutions for poorly water-soluble molecules and other challenging pharmaceutical development projects.

Ascendia formulates products for injection (IV, SC or IM); transdermal, ophthalmic or nasal delivery; and both immediate-release and controlled-release products for oral administration. We have three technology platforms – [EmulSol for producing nanoemulsions](https://ascendiacdmo.com/technologies/emulsol/), [AmorSol for creating amorphous solid dispersions](https://ascendiacdmo.com/technologies/amorsol/), and [NanoSol for formulating nano-particles](https://ascendiacdmo.com/technologies/nanosol/). For more information, please visit Ascendia’s website at [www.ascendiapharma.com](https://ascendiacdmo.com/).

[View full post](https://ascendiacdmo.com/newsroom/2017/01/06/ascendia-pharmaceuticals-announces-issuance-of-a-new-patent-on-its-asd-002-program-for-acute-coronary-syndrome)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "ascendia"
  },
  "dateModified" : "2024-12-01T07:11:46.116Z",
  "datePublished" : "2017-01-06T05:00:00Z",
  "headline" : "ASCENDIA PHARMACEUTICALS ANNOUNCES A NEW PATENT ON ITS ASD-002 PROGRAM",
  "image" : {
    "@type" : "ImageObject",
    "height" : 436,
    "url" : "https://19566523.fs1.hubspotusercontent-na1.net/hubfs/19566523/Imported_Blog_Media/blog-cover-2.jpg",
    "width" : 2552
  },
  "mainEntityOfPage" : "https://ascendiacdmo.com/newsroom/2017/01/06/ascendia-pharmaceuticals-announces-issuance-of-a-new-patent-on-its-asd-002-program-for-acute-coronary-syndrome",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Newsroom"
  }
}
```